↑ トップへ　← 戻る

Target Gene/Pathway（薬物標的遺伝子／パスウェイリスト）💬 Info on mouse-over

e.g. Sirolimus, アダリムマブ, MAP2K

ABCDEFGH I JKLMNOPQRSTUVWXYZother

147 / 286 pathways

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related		 KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
2 Acute myeloid leukemia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
3 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
4 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
5 African trypanosomiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
6 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
7 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
8 Alcoholism 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
9 Allograft rejection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
10 Alzheimer disease 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
11 Alzheimer disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
12 Alzheimer disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
13 Amoebiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
14 AMPK signaling pathway 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
15 AMPK signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
16 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
17 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
18 Antifolate resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
19 Antigen processing and presentation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
20 Apelin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
21 Apelin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
22 Apoptosis 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
23 Apoptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
24 Asthma 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
25 Autophagy - animal 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
26 Autophagy - animal 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
27 Autophagy - other 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
28 B cell receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
29 Bile secretion 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
30 Bladder cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
31 Bladder cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
32 Breast cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
33 Breast cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
34 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
35 Calcium signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
36 cAMP signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
37 Cellular senescence 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
38 Cellular senescence 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
39 Central carbon metabolism in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
40 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
41 cGMP-PKG signaling pathway 💬
 3件: ADRA2A, ADRA2B, ADRA2C 💬 D00514 💬 Dexmedetomidine 12件:  2 ,  4 ,  6 , 21, 34, 46, 70, 113, 212, 215, 226, 280 💬
42 cGMP-PKG signaling pathway 💬
 3件: ADRA2A, ADRA2B, ADRA2C 💬 D01205 💬 Dexmedetomidine 12件:  2 ,  4 ,  6 , 21, 34, 46, 70, 113, 212, 215, 226, 280 💬
43 cGMP-PKG signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
44 Chagas disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
45 Chemokine signaling pathway 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
46 Choline metabolism in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
47 Choline metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
48 Cholinergic synapse 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
49 Chronic myeloid leukemia 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
50 Colorectal cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
51 Colorectal cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
52 Complement and coagulation cascades 💬
 1件: SERPINC1 💬 D07510 💬 Heparin 11件: 60, 70, 79, 84, 107, 224, 226, 280, 299, 316, 317 💬
53 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
54 Cushing syndrome 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
55 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
56 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
57 Dilated cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
58 EGFR tyrosine kinase inhibitor resistance 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
59 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
60 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
61 Endocrine resistance 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
62 Endocrine resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
63 Endometrial cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
64 Epstein-Barr virus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
65 ErbB signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
66 ErbB signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
67 Estrogen signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
68 Estrogen signaling pathway 💬
 1件: OPRM1 💬 D00845 💬 Sufentanil 2件: 70, 280 💬
69 Estrogen signaling pathway 💬
 1件: OPRM1 💬 D05938 💬 Sufentanil 2件: 70, 280 💬
70 Fc epsilon RI signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
71 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
72 Fc gamma R-mediated phagocytosis 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
73 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
74 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
75 Focal adhesion 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
76 Focal adhesion 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
77 FoxO signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
78 Gap junction 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
79 Gastric cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
80 Gastric cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
81 Glioma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
82 Glioma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
83 GnRH secretion 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
84 GnRH signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
85 Graft-versus-host disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
86 Growth hormone synthesis, secretion and action 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
87 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
88 Hematopoietic cell lineage 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
89 Hepatitis B 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
90 Hepatitis B 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
91 Hepatitis C 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
92 Hepatitis C 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
93 Hepatocellular carcinoma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
94 Hepatocellular carcinoma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
95 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
96 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
97 HIF-1 signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
98 HIF-1 signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
99 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
100 Human cytomegalovirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
101 Human cytomegalovirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
102 Human cytomegalovirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
103 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
104 Human immunodeficiency virus 1 infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
105 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
106 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
107 Human papillomavirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
108 Human papillomavirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
109 Human papillomavirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
110 Human papillomavirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
111 Human T-cell leukemia virus 1 infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
112 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
113 Huntington disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
114 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
115 IL-17 signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
116 Inflammatory bowel disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
117 Influenza A 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
118 Influenza A 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
119 Insulin resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
120 Insulin resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
121 Insulin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
122 Insulin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
123 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
124 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
125 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
126 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
127 Legionellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
128 Leishmaniasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
129 Long-term depression 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
130 Long-term potentiation 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
131 Longevity regulating pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
132 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
133 Malaria 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
134 MAPK signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
135 MAPK signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
136 MAPK signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
137 Melanogenesis 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
138 Melanoma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
139 Metabolic pathways 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
140 MicroRNAs in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
141 MicroRNAs in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
142 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
143 Morphine addiction 💬
 1件: OPRM1 💬 D00845 💬 Sufentanil 2件: 70, 280 💬
144 Morphine addiction 💬
 1件: OPRM1 💬 D05938 💬 Sufentanil 2件: 70, 280 💬
145 mTOR signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
146 mTOR signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
147 mTOR signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
148 Natural killer cell mediated cytotoxicity 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
149 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
150 Necroptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
151 Neuroactive ligand-receptor interaction 💬
 3件: ADRA2A, ADRA2B, ADRA2C 💬 D00514 💬 Dexmedetomidine 12件:  2 ,  4 ,  6 , 21, 34, 46, 70, 113, 212, 215, 226, 280 💬
152 Neuroactive ligand-receptor interaction 💬
 3件: ADRA2A, ADRA2B, ADRA2C 💬 D01205 💬 Dexmedetomidine 12件:  2 ,  4 ,  6 , 21, 34, 46, 70, 113, 212, 215, 226, 280 💬
153 Neuroactive ligand-receptor interaction 💬
 1件: OPRM1 💬 D00845 💬 Sufentanil 2件: 70, 280 💬
154 Neuroactive ligand-receptor interaction 💬
 1件: OPRM1 💬 D05938 💬 Sufentanil 2件: 70, 280 💬
155 Neurotrophin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
156 Neutrophil extracellular trap formation 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
157 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
158 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
159 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
160 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
161 Non-small cell lung cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
162 Oocyte meiosis 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
163 Osteoclast differentiation 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
164 Osteoclast differentiation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
165 Oxytocin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
166 Pancreatic cancer 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
167 Pancreatic cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
168 Pancreatic cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
169 Parathyroid hormone synthesis, secretion and action 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
170 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
171 Pathways in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
172 Pathways in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
173 Pathways in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
174 Pathways of neurodegeneration - multiple diseases 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
175 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
176 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
177 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
178 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
179 Pertussis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
180 Phospholipase D signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
181 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
182 PI3K-Akt signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
183 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
184 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
185 Prion disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
186 Progesterone-mediated oocyte maturation 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
187 Prolactin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
188 Prostate cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
189 Prostate cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
190 Proteoglycans in cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
191 Proteoglycans in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
192 Proteoglycans in cancer 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
193 Proteoglycans in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
194 Rap1 signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
195 Rap1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
196 Ras signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
197 Ras signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
198 Regulation of actin cytoskeleton 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
199 Relaxin signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
200 Relaxin signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
201 Renal cell carcinoma 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
202 Renal cell carcinoma 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
203 Rheumatoid arthritis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
204 Rheumatoid arthritis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
205 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
206 Salmonella infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
207 Salmonella infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
208 Serotonergic synapse 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
209 Shigellosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
210 Shigellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
211 Signaling pathways regulating pluripotency of stem cells 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
212 Sphingolipid signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
213 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
214 Spinocerebellar ataxia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
215 Systemic lupus erythematosus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
216 T cell receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
217 T cell receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
218 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
219 TGF-beta signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
220 Th17 cell differentiation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
221 Thermogenesis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
222 Thyroid cancer 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
223 Thyroid hormone signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
224 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
225 TNF signaling pathway 💬
 1件: MAP2K1 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
226 TNF signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
227 Toll-like receptor signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
228 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
229 Toxoplasmosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
230 Tuberculosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
231 Type I diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
232 Type II diabetes mellitus 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
233 Type II diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
234 Vascular smooth muscle contraction 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
235 VEGF signaling pathway 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
236 VEGF signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
237 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
238 Yersinia infection 💬
 2件: MAP2K1, MAP2K2 💬 D10175 💬 Trametinib 4件:  2 , 34, 279, 280 💬
239 Yersinia infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬

先頭へ